Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.
| Revenue (TTM) | $106.73M |
| Gross Profit (TTM) | $57.51M |
| EBITDA | $-134.18M |
| Operating Margin | -121.60% |
| Return on Equity | -73.70% |
| Return on Assets | -29.20% |
| Revenue/Share (TTM) | $1.91 |
| Book Value | $3.75 |
| Price-to-Book | 7.64 |
| Price-to-Sales (TTM) | 16.07 |
| EV/Revenue | 14.77 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 59.90% |
| Shares Outstanding | $59.56M |
| Float | $33.72M |
| % Insiders | 5.22% |
| % Institutions | 101.84% |
Volatility is currently contracting
KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences:
KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.
Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by improved payer mix, scale, and supplier leverage, validating its unit economics story. Despite strong top-line momentum and raised FY27 guidance, profitability remains distant with a $44M net loss and $32M quarterly cash burn.
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company's executive leadership team.
Kestra Medical Technologies, Ltd. (KMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
KIRKLAND, Wash., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report first quarter fiscal 2027 financial results after the market closes on Monday, September 14.
KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience. In this newly created role, Mr. Kopf will lead the patient experience from approval of a patient order through completion of therapy and device return, aligning the people, processes and technology that support providers and their patients throughout the use of the ASSURE® WCD.
Kestra Medical Technologies, Ltd. (KMTS) saw its shares surge in the last session with trading volume being higher than average.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KMTS and any ticker you trade — then tracks every position and per-strategy win rate.
